What is the appropriate management for a patient with a blood urea nitrogen of 28 mg/dL and a urine micro‑albumin‑to‑creatinine ratio of 635 mg/g?

Management of Severely Increased Albuminuria with Elevated BUN

This patient requires immediate nephrology referral and urgent initiation of ACE inhibitor or ARB therapy regardless of baseline blood pressure, as the urine albumin-to-creatinine ratio of 635 mg/g represents severely increased albuminuria (≥300 mg/g) indicating advanced kidney damage with very high risk for end-stage renal disease and cardiovascular mortality. 1

Immediate Risk Stratification and Actions

Calculate eGFR and Determine CKD Stage

• Measure serum creatinine and calculate eGFR using the CKD-EPI equation to establish baseline kidney function and determine CKD stage 1, 2
• The BUN of 28 mg/dL is mildly elevated and warrants correlation with eGFR to assess severity of kidney dysfunction 3
• Mandatory immediate nephrology referral for ACR ≥300 mg/g, which defines severely increased albuminuria 1

Confirm Persistence of Albuminuria

• Repeat ACR measurement to confirm persistence, as CKD diagnosis requires abnormal kidney markers for ≥3 months 2
• Use first morning urine sample for optimal accuracy 3
• A single elevated ACR does not establish chronicity and requires confirmation 2

Pharmacologic Intervention

Initiate Renin-Angiotensin System Blockade

• Start ACE inhibitor or ARB immediately, regardless of baseline blood pressure, with target blood pressure <130/80 mmHg 1, 2
• ACE inhibitors and ARBs provide specific antiproteinuric effects beyond blood pressure lowering 1, 4
• Titrate to maximum tolerated doses for optimal antiproteinuric effect 5

Expected Hemodynamic Changes

• Serum creatinine rise ≤30% after initiating ACE inhibitors or ARBs is predictable and does NOT constitute acute kidney injury—continue therapy unless volume depletion is present 2
• Re-assess eGFR and potassium 2-4 weeks after starting or adjusting doses 2

Additional Cardiovascular Risk Reduction

• Target LDL <100 mg/dL and limit saturated fat to <7% of total calories 1
• Consider SGLT2 inhibitor if diabetes is present and residual albuminuria persists despite RAS inhibitor therapy 2
• Initial eGFR decline ≤30% with SGLT2 inhibitors is expected and should not prompt discontinuation 2

Monitoring Strategy

Frequency Based on CKD Stage

• If eGFR 30-59 mL/min/1.73 m² (Stage 3): Monitor ACR and eGFR every 3 months 1, 2
• If eGFR >60 mL/min/1.73 m² (Stage 1-2): Monitor every 6 months 1
• If eGFR 15-29 mL/min/1.73 m² (Stage 4): Monitor every 3-5 months with immediate nephrology referral 2
• If eGFR <30 mL/min/1.73 m²: Immediate nephrology referral is mandatory 1

Laboratory Parameters to Monitor

• Serum potassium at every visit due to hyperkalemia risk with ACE inhibitors/ARBs 2
• Serum electrolytes to assess for metabolic acidosis 2
• Hemoglobin with iron studies to identify anemia when eGFR <60 mL/min/1.73 m² 2
• Serum calcium, phosphate, PTH, and 25-hydroxyvitamin D when eGFR <60 mL/min/1.73 m² 2

Treatment Target

• Target ≥30% reduction in albuminuria as a therapeutic goal, particularly in diabetic patients 2
• Doubling of ACR on subsequent testing exceeds laboratory variability and warrants evaluation 2

Critical Thresholds Requiring Evaluation

eGFR Changes

• >20% decline in eGFR on subsequent testing exceeds expected variability and requires investigation 3, 2
• >30% decline after initiating hemodynamically active therapies requires evaluation for volume depletion or other causes 3, 2

Avoid Nephrotoxins

• Minimize exposure to NSAIDs and iodinated contrast, especially when eGFR <60 mL/min/1.73 m² 2
• Review all medications for nephrotoxic potential 2

Lifestyle Modifications

• Weight reduction if obese (target BMI <30) 6
• Sodium restriction <6 g per day 5, 6
• Smoking cessation 5
• Strict glucose control if diabetic (HbA1c <7%) 6

Common Pitfalls to Avoid

• Do not delay ACE inhibitor/ARB initiation while awaiting nephrology consultation—start immediately 1
• Do not discontinue ACE inhibitor/ARB for creatinine rise ≤30% unless volume depletion is present 2
• Do not rely on BUN alone for kidney function assessment—always calculate eGFR 3, 2
• Do not use dual ACE inhibitor + ARB therapy, as this increases adverse outcomes without additional benefit 4